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Available online 24 May 2016Peripheral bloodmononuclear cells (PBMCs)were collected from a clinically characterised, early onset Alzheimer's
disease patient, carries a heterozygous, pathogenic single nucleotide variation (SNV) in Presenilin1 (PSEN1) gene
(NM_000021.3(PSEN1):c.265GNC; ClinVar ID: 21r027). The PMBCs were reprogrammed with the human OSKM
transcription factors using the Sendai-virus delivery system. The transgene-free iPSC showedpluripotency veriﬁed
by immunocytochemistry for pluripotencymarkers and differentiated spontaneously towards the 3 germ layers in
vitro. Furthermore, the iPSC line showed normal karyotype. Our model might offer a good platform to study the
pathomechanism of familial AD, to identify early biomarkers and also for drug testing.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Blood samples were donated by a 55-year old female patient with
clinically and genetically characterised Alzheimer's disease by the Insti-
tute of Genomic Medicine and Rare Disorders, Semmelweis University,
Budapest (Hungary). The patient carries a heterozygous SNV in the
PSEN1 gene, which leads to an amino-acid change (p.Val89Leu) in the
protein sequence. The mutation has been shown to be associated with
pathologically conﬁrmed familial Alzheimer's disease, and computa-
tional modelling indicated that the mutation may alter the helical
structure of PSEN1protein (Queralt et al., 2002). The patient also carries
two possible benign synonymous SNVs in Presenilin 2 gene
(NM_000447.2(PSEN2):c.69TNC; rs ID: rs11405, homozygous and
NM_000447.2(PSEN2):c.129CNT; rs ID: rs6759, heterozygous).
To generate BIOT-7183-PSEN1 iPSC line (Fig. 1A) the four
“Yamanaka reprogramming factors” OCT3/4, SOX2, KLF4, and C-MYC
were delivered into PBMCs using the integration-free Sendai virus
gene-delivery method (Yang et al., 2008; Fusaki et al., 2009). The
iPSC-like colonies were picked after 20–27 days post-transduction.
Beginning from passage 5 of the iPSCs, the absence/presence of Sendai
virus vector was analysed by RT-PCR using Sendai virus vector (SeV) -
speciﬁc primers (Table 1). After 7 passages, the elimination of the
reprogramming vector was conﬁrmed in BIOT-7183-PSEN1 iPSC line
which was selected for further analysis (Fig. 1B).
The karyotype of the BIOT-7183-PSEN1 iPSC line was determined
by Giemsa-banding, proving normal diploid 46, XX karyotype, without
any detectable abnormalities (Fig. 1B). In parallel, the pathogenic
NM_000021.3(PSEN1):c.265GNC mutation was conﬁrmed with Sanger
sequencing in the newly established iPSC line (Fig. 1C).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1.Characterisation of BIOT-7183-PSEN1hiPSC lineA)Above:Morphologyof generated hiPSCs (4×) and representative immunoﬂuorescentmicrographs of iPSCs positive for stemcells
markers OCT3/4, NANOG and E-CADHERIN (in green). Alkaline phosphatase (AP) activity was also detected in iPSCs. Below: Spontaneously formed EBs in suspension culture (Day 5) and
after attachment and further differentiation (Day 14). Immunostainings for endodermal (GATA4), mesodermal (BRACHYURY) and ectodermal (βIII-TUBULIN) germ layers, markers (in
green). Nucleus is labelled with DAPI (in blue). B) RT-PCR veriﬁcation of the absence of Sendai-virus from the reprogrammed cells and karyogram showing normal 46 chromosomes
(XX). C) Sanger sequencing of the region containing the NM_000021.3(PSEN1): c.265GNC SNV in the newly established iPSC cell line.
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chemistry staining, using antibodies against human OCT3/4, E-
CADHERIN, and NANOG (Fig. 1A). The in vitro spontaneous differentia-
tion potential towards the three germ layer of the BIOT-7183-PSEN1
iPSC line was demonstrated by the expression of endodermal
(GATA4), mesodermal (BRACHYURY) and ectodermal (βIII-TUBULIN)
markers (Fig. 1A) (Itskovitz-Eldor et al., 2000; Carpenter et al., 2003).
Materials and methods
Reprogramming of peripheral blood mononuclear cells (PBMC)
PBMCs were isolated within 2 h post-collection using the
Vacutainer® CPT™ Cell Preparation Tubewith SodiumHeparin, (BD Bio-
sciences) and separated by centrifugation (1800 rcf, 30 min, room tem-
perature (RT). The freshly isolated PBMCs were seeded (0.5 × 106
cells) in ExpansionMedium (EM): QBSF-60medium (Quality Biological)Table 1
Primers used in the study.
Gene symbol Nucleotide change Protein change
PSEN1 c.265GNC (NM_000021.3) p.Val89Leu
SeV
RPS18Ssupplemented with 50 μg/ml Ascorbic acid, 1% Penicillin/Streptomycin,
50 ng/ml SCF (R&D systems), 10 ng/ml IL-3 (R&D systems), 2 U/ml
EPO (R&D systems), 40 ng/ml IGF-1 (R&D systems) and 1 μMDexameth-
asone. Nine days later (Day 0) the cells were transduced by Sendai-virus
delivery using the CytoTune®-iPS 2.0 Sendai Reprogramming Kit (Ther-
mo Fisher Scientiﬁc), following the manufacturer's instruction. Brieﬂy,
the cells were transduced on 1w/24wp in 1 ml EM supplemented with
4 μg polybrene. The calculated volumes of each of the three CytoTune™
2.0 Sendai-virus (SeV) was added to the cells using MOI of 5-5-3 (KOS
MOI = 5, hc-Myc MOI = 5, hKlf4 MOI = 3). The cell containing plate
was centrifuged (900 rcf, 90min, RT) and incubated for 24 h. The follow-
ing day the cells were collected, centrifuged (300 rcf, 5 min, RT) and
seeded in fresh EM (Day 1). Two days later (Day 3) the cells were passed
onto a 6 cm dish covered with 0.1% gelatine and 0.65 × 106Mitomycin C
treated-MEF in QBSF-60 medium (Quality Biological) supplemented
with 50 μg/ml Ascorbic acid. Seven days post-transduction (Day 7) the
medium was replaced with HESC medium: DMEM/F12, 20% KnockoutFwd and Rvs primers (5′-3′) PCR product (bp)
TGACGGGTCTGTTGTTAATCC
492
TCGCTCTCTCAACTGCTCCT
GGATCACTAGGTGATATCGAGC
181
ACCAGACAAGAGTTTAAGAGATATGTATC
TTAAGGGTGTGGGCCGAAGA
142
GGGATCTTGTACTGGCGTGGA
Table 2
Antibodies used for immunocytochemistry.
Antibody Dilution Company (Cat #)
Pluripotency
mouse anti-E-CADHERIN 1:1000
Thermo Fisher Scientiﬁc
(13-1700)
mouse anti-OCT4 1:50 Santa Cruz Biotechnologies (sc-5279)
goat anti-hNANOG 1:50 R&D (AF1997)
In vitro differentiation
rabbit anti-β-III-TUBULIN 1:2000 Covance (PRB-435P)
rabbit anti-BRACHYURY T 1:50 Santa Cruz Biotechnologies (sc-20109)
mouse anti-GATA4 1:50 Santa Cruz Biotechnologies (sc-25310)
Secondary antibodies
Alexa Fluor 488 donkey anti-goat IgG 1:2000 Thermo Fisher Scientiﬁc (A-11055)
Alexa Fluor 488 donkey anti-mouse IgG 1:2000 Thermo Fisher Scientiﬁc (A-21202)
Alexa Fluor 488 donkey anti-rabbit IgG 1:2000 Thermo Fisher Scientiﬁc (A-21206)
Alexa Fluor 488 donkey anti-mouse IgM 1:2000 Thermo Fisher Scientiﬁc (A-21r42)
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0.1 mM β-mercaptoethanol, 0.5% Pen/Strep, 10 ng/ml bFGF and supple-
mented with 50 μg/ml Ascorbic acid. The colonies with an ES-like ap-
pearance were manually isolated based on morphology between Day
21 to 27 post-transduction and cultured as iPSCs thereafter. Human
iPSC culturesweremaintained onplates coatedwithMatrigel (BDBiosci-
ences) in mTESR-1 medium (Stem Cell Technologies) following the
manufacturer's instruction (Fig. 1A). All cells were cultured at 37 °C in
humidiﬁed atmosphere containing 5% CO2.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated from cultured cells with RNeasy Micro Kit
(Qiagen) and reverse transcribed corresponding to SuperScript III Re-
verse Transcriptase protocol (Thermo Fisher Scientiﬁc). The RT-PCR re-
action was performed using GoTaq Hot Start Green Master Mix
(Promega). To conﬁrm the transgene-free status of the iPSC lines, SeV
speciﬁc primers were used described in CytoTune®-iPS 2.0 Sendai
Reprogramming Kit protocol (Thermo Fisher Scientiﬁc; Table 1).
In vitro spontaneous differentiation
The iPSCs were harvested according to the mTeSR-1 kit protocol
(StemCell Technologies) and the cell clumpswere plated on lowattach-
ment dishes in mTeSR medium. Five days later the embryoid bodies
(EBs) that had formed were plated on 24-well plates containing cover
slips (3–4 EBs/well), covered with 0.1% gelatin in differentiation medi-
um: DMEM, 20% FBS, 1% MEM Non-Essential Amino Acid Solution,
0.1 mM β-mercaptoethanol, 1% Pen/Strep. The medium was changed
in every secondday hereafter. The cellswere ﬁxed onday 14 of differen-
tiation with 4% PFA for ICC staining speciﬁc for the 3 germ layers.
Immunocytochemistry (ICC)
The expression of speciﬁc pluripotency and germ layer markers
were analysed using conventional ICC staining. Cells were ﬁxed in 4%
PFA (20 min, RT), permeabilized with 0.1% Triton X-100 (5 min, RT)
and blocked in 1% bovine serum albumin (1 h, RT). The cells were incu-
bated with primary antibodies (overnight at 4 °C) and visualized with
secondary antibodies. For nuclei counterstaining 0.2 μg/ml DAPI
(20 min, RT) was used. The antibodies and applied dilutions are listed
in Table 2. The cells were observed under ﬂuorescent microscope
equipped with 3D imaging module, (Axio Imager system with
ApoTome; Carl Zeiss) controlled by AxioVision 4.8.1 microscope soft-
ware (Carl Zeiss).
Alkaline phosphatase (AP) staining
For detecting Alkaline phosphatase activity the 4% PFA ﬁxed cells
(20 min, RT) were stained AP solution (29.7 mM TRIS base; 6 mMma-
leic acid, pH 8.5–9.0; with 0.08% MgCl2, 10.8 mM Naphtol-As MXPhosphate; 23 μM Fast Red TR Salt; all from Sigma Aldrich) for 30 min
(RT). Samples were observed with Axio Imager system (Carl Zeiss).
Karyotyping
Cells were treated with KaryoMAX® Colcemid™ Solution (Thermo
Fisher Scientiﬁc) and processed with standard methods. Standard
Giemsa-banded karyotypewas performed by Istenhegyi GeneDiagnostic
Center, Budapest (Hungary) and a minimum of 20 metaphases were
analysed. The chromosomeswere classiﬁed according to the Internation-
al System for Human Cytogenetic Nomenclature (ISCN).
Sanger sequencing
To conﬁrm the presence of the pathogenic PSEN1 SNV in the newly
established iPS cell line PCR primers were designed to the region of in-
terest (Table 1). PCR reactions were performed using Phusion Hot Start
II High-Fidelity DNA Polymerase (Thermo Fisher Scientiﬁc) and puriﬁed
with the PCR extract mini Kit (5PRIME, Hamburg, Germany). Speciﬁc
PCRproductswere sequenced directly using anABI Prism3130xlGenet-
ic Analyzer (Applied Biosystems) and BigDye Terminator Cycle Se-
quencing v3.1 Kit (Applied Biosystems).
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